Orphazyme to Present at BioCentury 25th Annual NewsMakers in the Biotech Industry

Orphazyme A/S
Investor news                                                                                                                                                        
No. 09/2018                                                                                                                                                           
Company Registration No. 32266355

Copenhagen, September 6, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Anders Hinsby, Chief Executive Officer at Orphazyme, will be presenting at the BioCentury 25^th Annual NewsMakers in the Biotech Industry in New York, USA on September 7, 2018 at 9.30 AM EDT.

For additional information, please contact
Orphazyme A/S
Anders Hinsby, CEO                             +45 31 44 31 39

About Orphazyme A/S
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com.  

Attachment